Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation.

Blood
Christoph SchmidAcute Leukemia Working Party of the European Group of Blood and Bone Marrow Transplantation

Abstract

To analyze the influence of distinct combinations of molecular aberrations on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for cytogenetically normal acute myeloid leukemia (CN-AML), a retrospective registry analysis was performed on 702 adults undergoing HSCT in first complete remission (CR). Patients were grouped according to presence or absence of NPM1 mutations (NPM1(mut)) and FLT3 internal tandem duplications (FLT3-ITD). Double-negative patients were evaluated for mutations of the CCAAT/enhancer binding protein α gene (CEBPα). The influence of genotypes on relapse, non-relapse mortality, leukemia-free survival (LFS) and overall survival (OS), and a prognostic classification combining NPM1/FLT3-ITD profile and classical risk factors were calculated. Two-year OS from HSCT was 81 ± 5% in NPM1(mut)/FLT3(wt), 75 ± 3% in NPM1(wt)/FLT3(wt), 66 ± 3% in NPM1(mut)/FLT3-ITD, and 54 ± 7% in NPM1(wt)/FLT3-ITD (P = .003). Analysis of CEBPα among patients with NPM1(wt)/FLT3(wt) revealed excellent results both in patients with CEBPα(mut) and with a triple negative genotype (2-year OS: 100%/77 ± 3%). In a Cox-model of predefined variables, age, FLT3-ITD and >1 course of chemotherapy to reach CR were risk factors ...Continue Reading

Associated Clinical Trials

References

Jan 19, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claudia D BaldusGerhard Ehninger
Aug 17, 2006·Blood·Soheil MeshinchiJerald P Radich
Feb 22, 2007·Blood·Martin BornhäuserUNKNOWN AML SHG 96 study group
May 3, 2008·The New England Journal of Medicine·Richard F SchlenkUNKNOWN German-Austrian Acute Myeloid Leukemia Study Group
Dec 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Annika DufourKarsten Spiekermann
Mar 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Farhad RavandiHagop M Kantarjian
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciHartmut Döhner
Jun 3, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christoph RölligGerhard Ehninger
Dec 15, 2011·Blood·Christoph SchmidUNKNOWN Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Feb 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Salut BrunetVanderson Rocha
Jul 7, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Gaëlle LabouréStéphane Vigouroux
Feb 5, 2013·Blood·Marta PratcoronaUNKNOWN Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Mar 3, 2015·Bone Marrow Transplantation·R Reshef, D L Porter

❮ Previous
Next ❯

Citations

Mar 15, 2016·Bone Marrow Transplantation·A E Perl, S M Luger
Apr 5, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Saiko KurosawaTakahiro Fukuda
May 15, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daniela DamianiRenato Fanin
Nov 3, 2016·Bone Marrow Transplantation·A M BrunnerY B Chen
Jul 16, 2016·American Journal of Hematology·Elihu Estey
Aug 2, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Marlise R LuskinRan Reshef
Sep 18, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Betty Ky Hamilton
Jul 2, 2016·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Ruifang SunKen H Young
Oct 25, 2016·Bone Marrow Transplantation·A AntarA Bazarbachi
Nov 3, 2016·Nature Reviews. Clinical Oncology·Aaron GoodmanRazelle Kurzrock
Nov 29, 2016·European Journal of Haematology·Christina RautenbergThomas Schroeder
Jan 4, 2018·Blood Advances·Alexander E Perl
Oct 27, 2017·Expert Review of Hematology·Marlise R Luskin, Daniel J DeAngelo
Jan 10, 2019·Current Opinion in Hematology·Shyam K PoudelLeland Metheny
Jan 18, 2019·Leukemia & Lymphoma·Jan Philipp BewersdorfAmer M Zeidan
Sep 26, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K HeidrichUNKNOWN Study Alliance Leukemia (SAL)
Jan 11, 2020·Leukemia·Ahmad I AntarAli Bazarbachi
Feb 9, 2020·Current Hematologic Malignancy Reports·Bradley D Hunter, Yi-Bin Chen
Apr 9, 2020·International Journal of Hematology·Melanie MärklinJonas S Heitmann
Jun 5, 2020·International Journal of Hematology·Saiko KurosawaTakahiro Fukuda
Apr 7, 2019·Bone Marrow Transplantation·Rafael F DuarteUNKNOWN European Society for Blood and Marrow Transplantation (EBMT)
Nov 9, 2019·Therapeutic Advances in Hematology·Abdul Hamid BazarbachiAli Bazarbachi
Mar 26, 2020·Blood Advances·Mark Levis, Alexander E Perl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.